Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Sarcoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 101Etoposide 60Carboplatin 55Vincristine 51Filgrastim 49Topotecan 44Temozolomide 44Melphalan 44Isotretinoin 44Doxorubicin 44Irinotecan 42Cisplatin 353-Iodobenzylguanidine 34Peripheral Blood Stem Cell Transplantation 31dinutuximab 30Granulocyte Colony-Stimulating Factor 30Radiotherapy 29sargramostim 28Granulocyte-Macrophage Colony-Stimulating Factor 25Busulfan 22Magnetic Resonance Spectroscopy 19aldesleukin 18Thiotepa 18fludarabine 17Interleukin-2 17humanized 3F8 anti-GD2 monoclonal antibody 16etoposide phosphate 16naxitamab 15Ifosfamide 15Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroblastoma × LY2940680 × CNS × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡